Plandai Biotechnology Expanding Footprint of Phytofare into U.S. with Continued Sales
04 May 2017 - 11:00PM
Marketwired
Plandai Biotechnology Expanding Footprint of Phytofare into U.S.
with Continued Sales
NEW YORK, NY-(Marketwired - May 04, 2017) - Plandaí
Biotechnology (OTCQB: PLPL) announced last week that its highly
bioavailable Phytofare® Catechin Complex would be the active
ingredient in Capital Brand's reformulated and soon-to-be released
SuperFood Fat Burning Boost®, which is used with the well-known
brand NutriBullet. This week we learned that thanks to a deal with
Coyne Healthcare - Plandaí's signature brand Phytofare® will make
its way to the U.S. and Europe as the star ingredient in Coyne
Healthcare's product Origine 8™.
Coyne Healthcare placed an order for 1.2 million of Plandaí's
Origine 8™ capsules, which is a product that not only uses the
highly bioavailable green tea extract, Phytofare® Catechin Complex,
but further enhances the bioavailability of the extract by using an
advanced liposome technology developed and clinically validated to
improve the delivery of nutritional substances.
Origine 8™ is a product that entraps all 8 of the catechins of
the tea plant, and according to Plandaí, it is the only
catechin-based capsule on the market backed by human clinical
studies that prove it has superior bioavailability.
Coyne Healthcare has already been selling Plandaí's unique
product in South Africa, but it now expects to launch Origine 8™
this month in both the U.S. and Europe. The good news for Plandaí
is that Coyne Healthcare has forecasted sales of 10.6 million
Origine 8™ capsules in 2017, and Coyne expects sales to further
increase to 24 million Origine 8™ capsules in 2018.
Coyne makes its products
(http://coynehealthcare.co.za/#products) available through
pharmacies, health food stores and medical practitioners, so for
both NutriBullet and Coyne Healthcare to bring Plandaí's signature
brand to the U.S., investors will have a great opportunity to
physically see their investment up close and personal.
Sales at Plandaí and the recognition that the company is gaining
globally, is clearly a response to the efforts made by the new COO,
Callum Cottrell-Duffield, well before now. He led the company's
sales and marketing team in its effort to grow the brand and expand
the company's footprint worldwide after Plandaí's signature product
was available for mass production and ready to market on a much
broader scale last year. His work to increase sales and marketing
throughout Africa, the United States, Europe, Asia and South
America by telling the Plandaí story, is starting to pay off now in
2017.
And, with brands like NutriBullet and Coyne Healthcare, who both
use and market only the highest quality ingredients in their
products, advertising the Phytofare® name, it shouldn't take long
for Plandaí to grow quite an impressive sales footprint
worldwide.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm
offering a platform for corporate stories to unfold in the media
with research reports, corporate videos, CEO interviews and feature
news articles.
We may from time to time include our own opinions about our
featured companies, their businesses, markets and opportunities.
Any opinions we may offer are solely our own, and are made in
reliance upon our rights under the First Amendment to the U.S.
Constitution, and are provided solely for the general opinionated
discussion of our readers and viewers. Our opinions should not be
considered to be complete, precise, accurate, or current investment
advice, or construed or interpreted as research. Any investment
decisions you may make concerning any company are solely your
responsibility based on your own due diligence. Our publications
are provided only as an informational aid. We encourage you to
invest carefully and read the investor information available at the
web site of the U.S. Securities and Exchange Commission at:
http://www.sec.gov. We also recommend as a general rule, that
before investing in any securities you consult with a professional
financial planner or advisor, and you should conduct a complete and
independent investigation before investing in any security after
prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We
hold no investment licenses and may not sell, offer to sell or
offer to buy any security. Our publications are not a
recommendation to buy or sell a security.
Section 17(b) of the 1933 Securities and Exchange Act requires
publishers who distribute information about publicly traded
securities for compensation, to disclose who paid them, the amount,
and the type of payment. In order to be in full compliance with the
Securities Act of 1933, Section 17(b), we are disclosing that SMMG
is compensated $5,000 per month by Plandai Biotechnology for
content development. Neither SMMG nor anyone associated with it
owns shares in PLPL.
For more information: www.stockmarketmediagroup.com.
Contact: Stock Market Media Group
info@stockmarketmediagroup.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Dec 2023 to Dec 2024